CRISPR Therapeutics AG (CRSP) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Zug, 스위스. 현재 CEO는 Samarth Kulkarni.
CRSP 을(를) 보유 IPO 날짜 2016-10-19, 393 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $5.46B.
CRISPR Therapeutics AG is a gene editing company headquartered in Zug, Switzerland, that develops gene-based medicines using its proprietary CRISPR/Cas9 technology platform, which enables precise modifications to genomic DNA. The company's clinical pipeline spans multiple therapeutic areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases, with lead programs such as CTX001 for beta-thalassemia and sickle cell disease, CTX110 and CTX120 for various cancers, and VCTX210 for type 1 diabetes. CRISPR also pursues in vivo gene-editing programs targeting liver, lung, muscle, and central nervous system diseases. The company has established strategic partnerships with major pharmaceutical and biotechnology firms including Bayer, Vertex Pharmaceuticals, ViaCyte, Nkarta, and Capsida Biotherapeutics to advance its therapeutic development efforts.
